8-K: Acurx Pharmaceuticals Announces Second Quarter 2024 Results and Provides Business Update

Acurx Pharmaceuticals reported its second quarter 2024 financial results, highlighted by progress in its ibezapolstat clinical program and regulatory advancements.

Summary

• Acurx Pharmaceuticals announced its financial results for the second quarter ended June 30, 2024, along with a business update.
• The company completed a successful End-of-Phase 2 meeting with the FDA, confirming Phase 3 readiness for ibezapolstat (IBZ) for the treatment of C. difficile infection.
• Acurx reached an agreement with the FDA on key elements for its international Phase 3 clinical trial program and the complete development plan for a New Drug Application (NDA).
• The company is preparing to submit requests for regulatory guidance to initiate clinical trials in the European Union, the United Kingdom, Japan, and Canada.
• Acurx received a new patent for IBZ from the USPTO, which covers the treatment of C. difficile infection while reducing recurrence and improving gut microbiome health, expiring in June 2042.
• The company submitted a request to the FDA for a meeting to review manufacturing processes and specifications for drug substance and final product.
• Acurx ended the quarter with $6.4 million in cash, compared to $7.5 million at the end of 2023.
• Research and development expenses for the quarter were $1.8 million, compared to $1.7 million in the same period last year.
• General and administrative expenses for the quarter were $2.3 million, compared to $1.7 million in the same period last year.
• The company reported a net loss of $4.1 million, or $0.26 per diluted share, for the quarter, compared to a net loss of $3.4 million, or $0.28 per diluted share, for the same period last year.

Sentiment

Score: 6

Explanation: The document presents a mix of positive clinical and regulatory progress with negative financial results. The successful Phase 2 meeting and patent are positive, but the increased net loss and decreased cash position temper the overall sentiment.

Positives

• The successful End-of-Phase 2 meeting with the FDA and agreement on Phase 3 trial plans are significant milestones.
• The new patent for IBZ provides a competitive advantage and extends market exclusivity until June 2042.
• The company is actively preparing for international clinical trials and regulatory submissions.
• The European Medicines Agency (EMA) approved Acurx's application to be designated as a small to medium sized enterprise (SME) in Europe, providing fee reductions and support.

Negatives

• The company's cash position decreased from $7.5 million at the end of 2023 to $6.4 million.
• The net loss for the quarter increased to $4.1 million from $3.4 million in the same period last year.
• General and administrative expenses increased by $0.6 million compared to the same quarter last year.

Risks

• The company's ability to successfully conduct and complete Phase 3 clinical trials for ibezapolstat is subject to various risks.
• Regulatory approvals in different regions are not guaranteed and may be subject to delays.
• The company's financial position may require additional funding in the future.
• The company's ability to successfully commercialize ibezapolstat is subject to market conditions and competition.

Future Outlook

Acurx plans to continue advancing ibezapolstat into international Phase 3 clinical trials, submit regulatory guidance requests in multiple regions, and present Phase 2 results at various scientific conferences. The company anticipates a meeting with the FDA regarding manufacturing processes in the fourth quarter.

Management Comments

• David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, hosted a conference call to discuss the results and provide a business update.

Industry Context

The development of new antibiotics, particularly for C. difficile, is critical due to increasing antibiotic resistance. Acurx's focus on a novel class of antibiotics and its progress in clinical trials aligns with the industry's need for innovative solutions to combat difficult-to-treat bacterial infections.

Comparison to Industry Standards

• Acurx's ibezapolstat is a novel DNA polymerase IIIC inhibitor, a different mechanism of action compared to existing C. difficile treatments like vancomycin and fidaxomicin.
• The company's focus on a Gram-positive selective spectrum (GPSS) antibiotic aims to minimize disruption to the gut microbiome, a key differentiator from broad-spectrum antibiotics.
• Other companies developing C. difficile treatments include Seres Therapeutics (SERE) with its microbiome-based therapy and Rebiotix (acquired by Ferring Pharmaceuticals) with its RBX2660 product, which is also a microbiome-based therapy.
• Acurx's progress in securing a new patent and advancing to Phase 3 trials positions it as a potential competitor in the C. difficile treatment market.
• The company's cash burn rate and net losses are typical for a clinical-stage biopharmaceutical company, but will need to be monitored closely as it progresses through Phase 3 trials.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased cash position.
• Employees may be encouraged by the progress in clinical trials and regulatory advancements.
• Customers (healthcare providers and patients) may benefit from the development of a new treatment option for C. difficile infection.
• Suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• Acurx will continue to advance ibezapolstat into international Phase 3 clinical trials.
• The company will submit requests for regulatory guidance to initiate clinical trials in the European Union, the United Kingdom, Japan, and Canada.
• Acurx will present Phase 2 results at various scientific conferences.
• The company anticipates a meeting with the FDA regarding manufacturing processes in the fourth quarter.

Key Dates

Keywords

ibezapolstat, C. difficile, antibiotics, clinical trials, FDA, Phase 3, patent, regulatory, biopharmaceutical, ACXP